oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2019 ( 77 )

2018 ( 66 )

2017 ( 90 )

2016 ( 98 )

Custom range...

Search Results: 1 - 10 of 32401 matches for " Peter Lipton "
All listed articles are free for downloading (OA Articles)
Page 1 /32401
Display every page Item
Making a Difference
Peter Lipton
Philosophica , 1993,
Abstract:
O melhor é bom o suficiente?
Peter Lipton
Princípios : Revista de Filosofia , 2010,
Abstract: Tradu o para o português do artigo “Is the Best Good Enough?”, publicado em Proceedings of the Aristotelian Society, vol. XCIII, parte 2, 1993, pp. 89-104.
Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer
Allan Lipton
Breast Cancer: Targets and Therapy , 2011, DOI: http://dx.doi.org/10.2147/BCTT.S16774
Abstract: ones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer Review (4542) Total Article Views Authors: Allan Lipton Published Date March 2011 Volume 2011:3 Pages 1 - 7 DOI: http://dx.doi.org/10.2147/BCTT.S16774 Allan Lipton Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, PA, USA Abstract: Bisphosphonates inhibit osteoclast-mediated bone resorption, thereby inhibiting the release of growth factors necessary to promote cancer cell growth, differentiation, and tumor formation in bone. These agents have demonstrated efficacy for delaying the onset and reducing the incidence of skeletal-related events in the advanced breast cancer setting, and have been shown to prevent cancer therapy-induced bone loss in the early breast cancer setting. Emerging clinical data indicate that the role of bisphosphonates in advanced and early breast cancer is evolving. Retrospective analyses and recent clinical trial data show that zoledronic acid may improve outcomes in some patients with breast cancer. Data from ABCSG-12 and ZO-FAST suggest that zoledronic acid may improve disease-free survival in the adjuvant breast cancer setting in postmenopausal women or women with endocrine therapy-induced menopause, and recent data from a predefined subset of the AZURE trial added to the anticancer story. However, the overall negative AZURE trial also raises questions about the role of bisphosphonates as an anticancer agent in patients with breast cancer. Overall, these data suggest that the addition of zoledronic acid to established anticancer regimens may have potential anticancer benefits in specific patient populations, although more studies are required to define its role.
An update of clinical issues from InSIGHT 2011
Lipton L
Hereditary Cancer in Clinical Practice , 2012, DOI: 10.1186/1897-4287-10-s2-a9
Abstract:
Encyclopedia of Women in Today’s World
Saundra Lipton
Theological Librarianship , 2012,
Abstract:
Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer
Allan Lipton
Breast Cancer: Targets and Therapy , 2011,
Abstract: Allan LiptonMilton S. Hershey Medical Center, Pennsylvania State University, Hershey, PA, USAAbstract: Bisphosphonates inhibit osteoclast-mediated bone resorption, thereby inhibiting the release of growth factors necessary to promote cancer cell growth, differentiation, and tumor formation in bone. These agents have demonstrated efficacy for delaying the onset and reducing the incidence of skeletal-related events in the advanced breast cancer setting, and have been shown to prevent cancer therapy-induced bone loss in the early breast cancer setting. Emerging clinical data indicate that the role of bisphosphonates in advanced and early breast cancer is evolving. Retrospective analyses and recent clinical trial data show that zoledronic acid may improve outcomes in some patients with breast cancer. Data from ABCSG-12 and ZO-FAST suggest that zoledronic acid may improve disease-free survival in the adjuvant breast cancer setting in postmenopausal women or women with endocrine therapy-induced menopause, and recent data from a predefined subset of the AZURE trial added to the anticancer story. However, the overall negative AZURE trial also raises questions about the role of bisphosphonates as an anticancer agent in patients with breast cancer. Overall, these data suggest that the addition of zoledronic acid to established anticancer regimens may have potential anticancer benefits in specific patient populations, although more studies are required to define its role.Keywords: anticancer, adjuvant therapy, bone metastasis, skeletal, zoledronic acid
Muon Collider: Plans, Progress and Challenges
Ronald Lipton
Physics , 2012,
Abstract: We in the physics community expect the LHC to uncover new physics in the next few years. The character and energy scale of the new physics remain unclear, but it is likely that data from the LHC will need to be complemented by information from a lepton collider which can provide for precise examination of new phenomena. We describe the concept, accelerator design, and detector R&D for a high energy Muon Collider as well as the challenges associated with the machine and its detector environment.
Homogenization and field concentrations in heterogeneous media
Robert Lipton
Mathematics , 2006,
Abstract: A multi-scale characterization of the field concentrations inside composite and polycrystalline media is developed. The analysis focuses on gradient fields associated with the intensive quantities given by the temperature and the electric potential. In the linear regime these quantities are modeled by the solution of a second order elliptic partial differential equation with oscillatory coefficients. Field concentrations are measured using the $L^p$ norm of the gradient of the solution for p>2. The analysis focuses on the case when the length scale of the heterogeneities are small relative to the domain containing them. Explicit lower bounds on the limit inferior of the sequence of $L^p$ norms are found in the fine scale limit These bounds provide a way to rigorously assess field concentrations generated by highly oscillatory microgeometies. Illustrative examples are provided that demonstrate the optimality of the lower bounds.
Cohesive Dynamics and Brittle Fracture
Robert Lipton
Mathematics , 2014,
Abstract: We formulate a nonlocal cohesive model for calculating the deformation state inside a cracking body. In this model a more complete set of physical properties including elastic and softening behavior are assigned to each point in the medium. We work within the small deformation setting and use the peridynamic formulation. Here strains are calculated as difference quotients. The constitutive relation is given by a nonlocal cohesive law relating force to strain. At each instant of the evolution we identify a process zone where strains lie above a threshold value. Perturbation analysis shows that jump discontinuities within the process zone can become unstable and grow. We derive an explicit inequality that shows that the size of the process zone is controlled by the ratio given by the length scale of nonlocal interaction divided by the characteristic dimension of the sample. The process zone is shown to concentrate on a set of zero volume in the limit where the length scale of nonlocal interaction vanishes with respect to the size of the domain. In this limit the dynamic evolution is seen to have bounded linear elastic energy and Griffith surface energy. The limit dynamics corresponds to the simultaneous evolution of linear elastic displacement and the fracture set across which the displacement is discontinuous. We conclude illustrating how the approach developed here can be applied to limits of dynamics associated with other energies that $\Gamma$- converge to the Griffith fracture energy.
Dynamic Brittle Fracture as a Small Horizon Limit of Peridynamics
Robert Lipton
Mathematics , 2013,
Abstract: We consider the nonlocal formulation of continuum mechanics described by peridynamics. We provide a link between peridynamic evolution and brittle fracture evolution for a broad class of peridynamic potentials associated with unstable peridynamic constitutive laws. Distinguished limits of peridynamic evolutions are identified that correspond to vanishing peridynamic horizon. The limit evolution is associated with dynamic brittle fracture and satisfies a dynamic energy inequality expressed in terms of the kinetic energy of the motion together with a bulk elastic energy and a Griffith surface energy. It corresponds to the simultaneous evolution of elastic displacement and brittle fracture with displacement fields satisfying the wave equation inside the cracking domain. The wave equation provides the dynamic coupling between elastic waves and the evolving fracture path inside the media. The elastic moduli, wave speed and energy release rate for the evolution are explicitly determined by moments of the peridynamic influence function and the peridynamic potential energy.
Page 1 /32401
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.